Gilead Sciences to buy Germany's Tubulis for up to $5B
Gilead Sciences, a major US pharma player, just announced it's acquiring Germany's Tubulis for up to $5 billion.
The move is all about boosting Gilead's cancer drug lineup, especially as some of its older patents expire and COVID-19 sales drop.
Tubulis stands out for its next-generation antibody-drug conjugates, basically, targeted chemotherapy that aims to hit cancer cells without harming healthy ones.
Deal includes TUB-040 and TUB-030
Gilead will pay $3.15 billion upfront and could add another $1.85 billion if certain milestones are met. This gives them access to promising drugs like TUB-040 (for ovarian and lung cancers) and TUB-030 (for multiple solid tumors).
Once the deal wraps up in the second quarter of 2026, Tubulis will become Gilead's dedicated research unit for these advanced cancer therapies.
Despite a small dip in Gilead's stock price after the news, this fits into its bigger plan to stay strong in oncology by snapping up innovative companies.